Isis Pharmaceuticals IncCompany Details

Get alertedif Isis Pharmaceuticals Inc gets funded!
United States
Detailed industries:biotechnology
Company description

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis’ broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis’ partner, Genzyme, plans to commercialize Isis’ lead product, KYNAMRO™, in the United States and Europe following regulatory approval. Isis’ patents provide strong and extensive protection for its drugs and technology.


Funding history

DateDeal sizeInvestors 
October 9th, 2014$18,000,000GlaxosmithklineView Deal
November 27th, 2013$3,000,000Glaxosmithkline GskView Deal
September 10th, 2013$100,000,000-View Deal
December 11th, 2012$31,000,000AstrazenecaView Deal
August 27th, 2012$201,250,000-View Deal
Create alert
Want to know when Isis Pharmaceuticals Inc gets funded?
Key people
Yasunori KanekoSenior Vice President and CFO
Skip KleinBoard of Directors
Joseph Klein, IiiBoard of Directors
Paul KlingensteinBoard Member, Board of Directors
Elizabeth L. HougenSenior Vice President, Finance and Chief Financial Officer
Brett P. MoniaSenior Vice President of Antisense Drug Discovery
Spencer R. BerthelsenBoard of Directors
Richard S. GearySenior Vice President of Development
Shawn Swaneymanagement positions
Stanley T. CrookeChairman of the Board and Chief Executive Officer
Please note that all data is automatically extracted and errors can occur.
The WhoGotFunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and complete.
Inaccurate Data? Help us improve WhoGotFunded: post a comment!